Nuklearmedizer Ken Herrmann übernimmt Position in Aufsichtsrat der Pentixapharm Holding AG

Berlin, October 28, 2024 – Prof. Dr. Ken Herrmann, an international consultant and leader of the Klinik voor Nuklearmedizin at the Universitätsklinikum Essen, who has served on the Aufsichtsraad of Pentixapharm Holding AG. De Ernennung Wurde Bereits auf der Aktionärsammlung im June 2024 beschlossen en trat mit der Eintragung der Abspaltung der Pentixapharm AG von der Eckert Ziegler SE ins Handelsregister in Kraft. Der Amtsantritt hat sich jedoch aufgrund ausstehender Genehmungen zur Aufnahme oneer bentätigkeit verzögert.

“With our friends, Ken Herrmann will come to our senses,” Dr. Andreas Eckert, Principal of Pentixapharm Holding AG. “Ken Herrmann is one of the leading clinicians in the field of radiopharmaceuticals. We will bring our expertise to bear on the profitability of our oncology pipeline, the Y90-PentixaTher and Ga68-PentixaFor zur Treatment and Diagnosis of Non-Hodgkin’s Lymphoma (NHL) umfasst.”

Prof. Herrmann is an international research expert in the field of nuclear medicine and nuclear medicine. Neben seiner Position at the Universitätsklinikum Essen is the Lehrstuhl of the Onkologie- und Theranostik-Ausschusses of the European Association of Nuclear Medicine (EANM). There is a editor of the Journal of Nuclear Medicine (JNM) and more than 700 deleted articles with öffentlicht.

After the Medizinstudium an der Charité Berlin und der Habilitation in Nuklearmedizin an der TU Munich ergänzte Prof. Dr. Herrmann studied with an Executive MBA from the University of Zurich. There is regular business operations at industry events, which support the annual conference of EANM and the Society of Nuclear Medicine and Molecular Imaging (SNMMI). It is noteworthy that Pentixapharm’s CXCR4 symposium at the last EANM is part of the 2. Boston Radionuclide Theranostics Forum, which was founded at that time by the Eckert Ziegler SE.

Prof. Dr. Herrmann has initiated an investigation into Frank Perschmann’s opinion. Please let us know if you would like to know more about Pentixapharm-Gründer Dr. Hakim Bouterfa as well as the Endocrinologist Prof. Dr. med. Marcus Quinkler, who noted his Heritage for the Entwicklung of Ga68-Pentixa in the first hyperaldosteronism, one of the Hauptursachen for the second hypertonia, einbringt.

Uber Pentixapharm

Pentixapharm is a radiopharmaceutical company based in Sitz in Berlin and Würzburg. The Unternehmen have innovative first-class radiopharmaceuticals, which are based on the CXCR4 receiver. Used both diagnostically and therapeutically, various haematological and solid tumors are characterized by cardiovascular, endocrine and inflammatory disorders.

Pentixapharm’s clinical pipeline utilizes PentixaTher, a Yttrium-90 base therapy for Non-Hodgkin Lymphome (NHL), and PentixaFor, a Gallium-68 based diagnostic. Clinical trials for both substances have begun with a dose-finding study for PentixaTher and a Phase III registrational study for PentixaFor in marginal zones in Europe. It is possible to use a diagnostic tool for primary hyperaldosteronism (PA) with Pentixa, a bedeuting Ursache for Bluthochdruck. Pentixapharm has conducted a Phase III trial of PentixaFor in PA before beginning work in Europe and in the US in the year 2025.

Please contact:

Pentixapharm Holding AG
Phillip Eckert, Investor Relations
(email protected)
Tel. +49 30 94893232
www.pentixapharm.com